MEDTOX Diagnostics
- Company typePrivate
- Founded1987
- HeadquartersBurlington, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
MEDTOX Diagnostics firmographics
Firmographics- Name
- MEDTOX Diagnostics
- Legal name
- MEDTOX Diagnostics, Inc.
- Website
- https://medtoxdiagnostics.com
- Company type
- Private
- Founded year
- 1987
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
MEDTOX Diagnostics industry classification
Industry- Product category
- Point-of-Care Drug Testing Devices
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Drug-of-Abuse & Toxicology Rapid Tests (Urine/saliva panels) (HLAHAOAG)
- akta.pro secondary industry
- Release Testing & Batch Certification (QC) (HLAGADAC)
Keywords
Where MEDTOX Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Burlington
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
MEDTOX Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D
Revenue model
- Drug Testing Devices and Consumables: MEDTOX generates revenue through the sale of drug testing devices (cassettes, cups) and related consumables. The company sells directly to hospitals, workplaces, criminal justice facilities, and clinical trial organizations. Products are available via sales representatives and direct reorder.
- MEDTOXScan Reader Hardware and Licensing: Sale of MEDTOXScan automated readers that read PROFILE-V cassette test results, combined with ongoing support services for laboratory information system integration and technical support.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
MEDTOX Diagnostics product offering
Product offeringCore offering
MEDTOX Diagnostics manufactures and sells FDA 510(k)-cleared rapid drug testing devices, including single-step immunoassay cassettes and cups that deliver qualitative urine drug screening results within minutes. The portfolio includes the MEDTOXScan automated reader system, multi-panel cassettes (PROFILE and VERDICT lines), EZ-SCREEN cups with on-board adulteration strips, and the Labcorp Fentanyl Test, all produced at its Burlington, North Carolina facility under ISO 13485:2016 quality certification.
Product overview
MEDTOX Diagnostics is a portfolio of drug testing devices and solutions, transitioning to Labcorp Point of Care in 2026. The company offers rapid, one-step immunoassay urine drug screening devices available in cassette and cup form, along with the MEDTOXScan automated reader system. Cassette products include PROFILE-II, PROFILE-IIA, PROFILE-II ER, VERDICT-II, and PROFILE-V (for MEDTOXScan), testing for 7-12 drugs of abuse. Cup products include EZ-SCREEN (HI) and EZ-SCREEN (LO), testing for up to 11 drugs. The MEDTOXScan reader automates cassette testing with barcode scanning, digital results, and laboratory information system connectivity. All devices are FDA 510(k)-cleared, manufactured in Burlington, North Carolina, with ISO 13485:2016 quality management system certification.
Differentiator
Problem solved
Functional benefit
Brands
- MEDTOXScan: Automated drug testing reader that provides screening results within 10 minutes, tests for up to 12 drugs of abuse.
- PROFILE
- VERDICT
- EZ-SCREEN
Quantifiable outcome
- Screening results delivered in 10 minutes
- +4 more outcomes
Companies that use MEDTOX Diagnostics
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
MEDTOX Diagnostics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
MEDTOX Diagnostics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- LabcorpcoreDuring 2026, the trade name for MEDTOX Diagnostics products will transition to Labcorp Point of Care. MEDTOX Diagnostics operates as part of Labcorp's point-of-care diagnostics portfolio, with their fentanyl test product line being marketed under the Labcorp Point of Care brand. Labcorp has launched the FDA-cleared fentanyl test manufactured by MEDTOX under the Labcorp branding.
Scale indicators5 records
Recent moves5 records
Expansion highlights4 records
MEDTOX Diagnostics competitors and assessment
Company assessmentDirect peers
- Abbott Toxicology (formerly Alere): Abbott's toxicology business (built on the Alere acquisition) sells rapid point-of-care drugs-of-abuse immunoassay devices and readers, directly competing with MEDTOX cassettes and cups across workplace, criminal justice, and clinical settings.
- Quest Diagnostics: Quest operates one of the largest US reference laboratory toxicology businesses, providing lab-based drug testing services and increasingly offering rapid point-of-care options — competing directly with MEDTOX for workplace, criminal justice, and clinical customers.
- Psychemedics Corporation: Psychemedics is a specialty drug-testing laboratory focused on hair follicle testing for drugs of abuse, serving employers, courts, and schools — competing with MEDTOX in the same end-markets via a different specimen matrix.
- Clinical Reference Laboratory: CRL provides lab-based drugs-of-abuse testing services to employers, government, and clinical trial sponsors, competing with MEDTOX's confirmatory lab workflow following on-site screening.
- Premier Biotech: Premier Biotech manufactures rapid urine-based drugs-of-abuse test cups and cassettes (similar SKU range to MEDTOX) and sells into workplace, clinical, and law enforcement channels — a closely comparable direct competitor in the rapid toxicology device category.
Broad incumbents
- Roche Diagnostics: Roche offers broad clinical chemistry, immunoassay, and toxicology menus through centralized lab analyzers (cobas) used by hospital laboratories — overlapping with MEDTOX's drug-screening applications, especially in clinical/hospital use cases.
- Siemens Healthineers: Siemens provides clinical chemistry and immunoassay analyzers (Atellica, ADVIA Centaur) widely used in hospital labs for drug screening confirmation, competing with MEDTOX's hospital-side toxicology workflow at the lab-confirmation stage.
- Labcorp: Labcorp is MEDTOX's parent company and a dominant reference lab for drugs-of-abuse confirmation testing — providing both distribution synergy and competitive overlap as Labcorp expands its Point of Care portfolio.
Emerging players
- OraSure Technologies: OraSure develops oral fluid collection devices (Intercept) used in workplace and criminal justice drug testing, representing a modality alternative to MEDTOX's urine-based immunoassays.
- Confirm Biosciences: Confirm Biosciences offers a portfolio of rapid urine drug test cups and saliva-based oral fluid drug testing kits, overlapping with MEDTOX's product line especially in workplace and at-home testing channels.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
MEDTOX Diagnostics social profiles
Digital presenceMEDTOX Diagnostics compliance and trust
Trust signalCompliance3 records
MEDTOX Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
MEDTOX Diagnostics leadership team
Management profileNumber of profiles
Profiles4 records
MEDTOX Diagnostics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MEDTOX Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MEDTOX Diagnostics
What does MEDTOX Diagnostics do?
MEDTOX Diagnostics manufactures and sells FDA 510(k)-cleared rapid drug testing devices, including single-step immunoassay cassettes and cups that deliver qualitative urine drug screening results within minutes. The portfolio includes the MEDTOXScan automated reader system, multi-panel cassettes (PROFILE and VERDICT lines), EZ-SCREEN cups with on-board adulteration strips, and the Labcorp Fentanyl Test, all produced at its Burlington, North Carolina facility under ISO 13485:2016 quality certification.
Is MEDTOX Diagnostics a public or private company?
MEDTOX Diagnostics is a private company. It is classified as corporate owned and is currently operating.
When was MEDTOX Diagnostics founded?
MEDTOX Diagnostics was founded in 1987. It employs 251 to 500 people.
Where is MEDTOX Diagnostics based?
MEDTOX Diagnostics is headquartered in Burlington, United States, in the North America region.
How does MEDTOX Diagnostics make money?
Two revenue lines are on record. Drug Testing Devices and Consumables are the primary driver. The others are MEDTOXScan Reader Hardware and Licensing.
Who are MEDTOX Diagnostics's main competitors?
Direct peers on record are Abbott Toxicology (formerly Alere), Quest Diagnostics, Psychemedics Corporation, Clinical Reference Laboratory and Premier Biotech. Broad incumbents are Roche Diagnostics, Siemens Healthineers and Labcorp. Emerging players are OraSure Technologies and Confirm Biosciences.
Does MEDTOX Diagnostics have an API?
No public API is recorded for MEDTOX Diagnostics.
What industry is MEDTOX Diagnostics in?
MEDTOX Diagnostics's product category is Point-of-Care Drug Testing Devices. Its primary akta.pro industry code is HLAHAOAG, Drug-of-Abuse & Toxicology Rapid Tests (Urine/saliva panels), with a secondary code of HLAGADAC, Release Testing & Batch Certification (QC). Its NAICS code is 325413 and its SIC code is 2835.